Adjuvant Camrelizumab Plus Chemoradiation Improves Survival in Resected Cholangiocarcinoma and Gallbladder Cancer: ACCORD Trial Results

Bile Duct Cancer (Cholangiocarcinoma), Gallbladder Cancer /

Camrelizumab plus chemoradiation improved 3-year OS to 58.2% vs 30.5% observation in resected cholangiocarcinoma/gallbladder cancer.

Adjuvant Camrelizumab Plus Chemoradiation Improves Survival in Resected Cholangiocarcinoma and Gallbladder Cancer: ACCORD Trial Results Read More »